Search Results | Blood | American Society of Hematology

1-20 of 99

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission

Blood (2022) 139 (9): 1330–1339.

DOI: https://doi.org/10.1182/blood.2021013289

Published: 2022

Includes: Supplemental data

Journal Articles

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Blood (2021) 138 (Supplement 2): LBA-6.

DOI: https://doi.org/10.1182/blood-2021-155068

Published: 2021

Journal Articles

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma

Blood (2021) 138 (Supplement 1): 1750.

DOI: https://doi.org/10.1182/blood-2021-151859

Published: 2021

Journal Articles

Characteristics, Management and Outcomes of Patients with Intravascular Lymphoma: A Mayo Clinic Experience

Karan Seegobin, Muhamad Alhaj Moustafa, Umair Majeed, Liuyan Jiang, David Menke, Ke Li, Mohamed A. Kharfan-Dabaja, Ernesto Ayala, Madiha Iqbal, Grzegorz S. Nowakowski, Thomas M. Habermann, Thomas E. Witzig, Patrick B. Johnston, Carrie A. Thompson, Stephen M. Ansell, Han W. Tun

Blood (2021) 138 (Supplement 1): 1452.

DOI: https://doi.org/10.1182/blood-2021-146408

Published: 2021

Journal Articles

Improved Clinical Outcome of Patients with Myelodysplastic Syndrome (MDS) Progressing after Hypomethylating Agent: In the Era of Novel Therapies

Ahmad Ghorab, Aref Al-Kali, Michelle A. Elliot, Mithun V. Shah, Jeanne M. Palmer, Hemant S. Murthy, Mohamed A. Kharfan-Dabaja, Mark R. Litzow, James M. Foran, Talha Badar

Blood (2021) 138 (Supplement 1): 3688.

DOI: https://doi.org/10.1182/blood-2021-150626

Published: 2021

Journal Articles

DDX41 Variant of Unknown Significance (VUS) Have Distinct Clinical and Diagnostic Features but Are Associated with Similar Prognosis and Co-Mutation Patterns As Pathogenic DDX41 : Analysis of the Mayo Clinic (MC) Myeloid Next-Generation Sequencing (NGS) Cohort

Talha Badar, Ahmad Nanaa, Rong He, Aref Al-Kali, David S. Viswanatha, Emily Godsey, Lisa Z. Sproat, Mohamed A. Kharfan-Dabaja, Mrinal M. Patnaik, Hassan B. Alkhateeb, Mark R. Litzow, James M. Foran

Blood (2021) 138 (Supplement 1): 3693.

DOI: https://doi.org/10.1182/blood-2021-145115

Published: 2021

Journal Articles

Trends in Utilization of Stored Cryopreserved Autologous Peripheral Hematopoietic Cells (APBHC) Intended for a Second (or beyond) Autologous Hematopoietic Cell Transplantation (AHCT) in Patients with Multiple Myeloma (MM): A Single Center Experience

Farah Yassine, Mohamed A. Kharfan-Dabaja, Athanasios Tsalatsanis, Vivek Roy, Abba C. Zubair, Hemant S. Murthy, Ernesto Ayala, Madiha Iqbal, Taimur Sher, Sikander Ailawadhi, Ricardo D Parrondo

Blood (2021) 138 (Supplement 1): 665.

DOI: https://doi.org/10.1182/blood-2021-152635

Published: 2021

Journal Articles

Unique Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (trALL) Following Therapy for Multiple Myeloma (MM)

Ricardo D Parrondo, Zaid Abdel Rahman, Michael G. Heckman, Mikolaj Wieczorek, Liuyan Jiang, Hassan B. Alkhateeb, Mark R. Litzow, Patricia Greipp, Taimur Sher, Leif Bergsagel, Rafael Fonseca, Vivek Roy, Angela Dispenzieri, Mohamed A. Kharfan-Dabaja, Hemant S. Murthy, Sikander Ailawadhi, James M. Foran

Blood (2021) 138 (Supplement 1): 2285.

DOI: https://doi.org/10.1182/blood-2021-151574

Published: 2021

Journal Articles

Primary Central Nervous System Involvement at Initial Diagnosis Remains an Independent Risk Factor for Relapse in Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation in CR1

Blood (2021) 138 (Supplement 1): 2901.

DOI: https://doi.org/10.1182/blood-2021-149695

Published: 2021

Journal Articles

Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy

Blood (2021) 138 (Supplement 1): 2527.

DOI: https://doi.org/10.1182/blood-2021-146119

Published: 2021

Journal Articles

A Calcineurin Inhibitor Free Graft Versus Host Disease (GVHD) Prophylaxis for Patients Undergoing Matched Related (MRD) and Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplant (Allo-HCT)

Madiha Iqbal, Felipe Andres Mendieta Nieto, Kaitlyn M Brannick, Zhuo Li, Hemant S. Murthy, James M. Foran, Vivek Roy, Mohamed A. Kharfan-Dabaja, Ernesto Ayala

Blood (2021) 138 (Supplement 1): 3893.

DOI: https://doi.org/10.1182/blood-2021-151845

Published: 2021

Journal Articles

Significance of Degree of HLA Disparity When Using Haploidentical Donors with T-Replete PBSC and Post-Transplantation Cyclophosphamide (PTCy) in Acute Myeloid Leukemia (AML) in First Complete Hematologic Remission (CR1)

Mohamed A. Kharfan-Dabaja, Myriam Labopin, Ernesto Ayala, Ali Bazarbachi, Didier Blaise, Yener Koc, Jan Vydra, Alessandro Busca, Luca Castagna, Yana Novis, Andrew McDonald, Claude-Eric Bulabois, Christoph Schmid, Concepcion Herrera Arroyo, Edouard Forcade, Fabio Ciceri, Jaime Sanz, Arnon Nagler, Mohamad Mohty

Blood (2021) 138 (Supplement 1): 3910.

DOI: https://doi.org/10.1182/blood-2021-149651

Published: 2021

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR

Hemant S. Murthy, MD, Kwang Woo Ahn, PhD, Noel Estrada-Merly, MS, Lohith Gowda, MD, Bhagirathbhai Dholaria, MBBS, Susan Bal, MDMBBS, Hassan B. Alkhateeb, MD, Deepa Jagadeesh, MDMPH, Betul Oran, MDMS, Ryotaro Nakamura, MD, Bart L. Scott, MD, Craig S. Sauter, MD, Francine M. Foss, MD, Mohamed A kharfan-Dabaja, MDMBA, Wael Saber, MD MS

Blood (2020) 136 (Supplement 1): 28–29.

DOI: https://doi.org/10.1182/blood-2020-134793

Published: 2020

Journal Articles

Impact of Cell of Origin (COO) on Long Term Outcomes Post Autologous Hematopoietic Cell Transplant in Patients with Relapsed/ Refractory Chemotherapy Sensitive De-Novo Diffuse Large B-Cell Lymphoma (DLBCL)

Madiha Iqbal, MBBS, Yennifer Gil, Jonas Paludo, MD, Allison C. Rosenthal, D.O., Zhou Li, MS, Manuel Beltran, David J. Inwards, MD, Luis F. Porrata, MD, Ivana Micallef, MD, Jose C Villasboas, MD, Patrick B. Johnston, Stephen M. Ansell, MD PhD, Craig B. Reeder, MD, Hemant S. Murthy, MD, Vivek Roy, MD, James M. Foran, MD, Han W. Tun, MD, Mohamed A. Kharfan-Dabaja, MDMBA, Ernesto Ayala, MD

Blood (2020) 136 (Supplement 1): 42–43.

DOI: https://doi.org/10.1182/blood-2020-136332

Published: 2020

Journal Articles

Superiority of Thiotepa-Containing Conditioning Regimens in Patients with Primary Diffuse Large B-Cell Lymphoma (DLBCL) of the Central Nervous System (CNS) Undergoing Autologous Hematopoietic Cell Transplantation (autoHCT)

Trent Wang, DO,MPH, Michael Scordo, MD, Kwang Woo Ahn, PhD, Stella Chen, MS, Mohamed A. Kharfan-Dabaja, MDMBA, Alex F. Herrera, MD, Mehdi Hamadani, MD, Craig S. Sauter, MD

Blood (2020) 136 (Supplement 1): 8–9.

DOI: https://doi.org/10.1182/blood-2020-137237

Published: 2020

Journal Articles

Management of Patients with Aggressive B Cell Non-Hodgkin Lymphoma after Relapse from Axicabtagene Ciloleucel: Single Center Real-World Experience

Jose V. Forero, MD, Paula A. Lengerke Diaz, MD, Eider F. Moreno Cortes, MD, Megan Melody, MD, Allison C. Rosenthal, D.O., Mohamed A. Kharfan-Dabaja, MDMBA, Januario E. Castro, MD

Blood (2020) 136 (Supplement 1): 43–44.

DOI: https://doi.org/10.1182/blood-2020-143168

Published: 2020

Journal Articles

Survival Outcomes in Blastic Plasmacytoid Dendritic Cell Neoplasm By First-Line Treatment and Stem Cell Transplant

Seongseok Yun, MDPhD, Onyee Chan, MD, Daniel Kerr, MDPhD, Nicole D. Vincelette, PhD, Afshan Idrees, MD MPH, Qianxing Mo, PhD, Kendra Sweet, MD, Jeffrey E. Lancet, MD, Mohamed A kharfan-Dabaja, MDMBA, Ling Zhang, MD, Lubomir Sokol, MD PhD

Blood (2020) 136 (Supplement 1): 15.

DOI: https://doi.org/10.1182/blood-2020-133391

Published: 2020

Journal Articles

Pre- Transplant Ferritin Predicts Overall Survival and Non-Relapse Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis

Xavier A Andrade-Gonzalez, MD, Ayalew Tefferi, MD, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Mrinal M. Patnaik, MDMBBS, Jeanne M. Palmer, MD, Mohamed A. Kharfan-Dabaja, MDMBA, Mark Litzow, MD, Mithun Vinod Shah, MD PhD, William J Hogan, MB, BCh, Hassan B. Alkhateeb, MD

Blood (2020) 136 (Supplement 1): 19–20.

DOI: https://doi.org/10.1182/blood-2020-141414

Published: 2020

Journal Articles

Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel)

Blood (2019) 134 (Supplement_1): 5343.

DOI: https://doi.org/10.1182/blood-2019-126594

Published: 2019

Journal Articles

Impact of Anti-CD19 CAR-T Axicabtagene Ciloleucel on Vaccine Titers of DTaP and MMR

Zaid Abdel Rahman, MD, Nicole Gannon, PA-C, Megan Melody, MD, Paul Muniz, RN, Ernesto Ayala, MD, Vivek Roy, MD, Lisa Brumble, Sikander Ailawadhi, MD, Taimur Sher, MD, James M. Foran, MD, Hemant S. Murthy, MD, Han W. Tun, MD, Candido E. Rivera, MD, Asher A. Chanan-Khan, MD, Abba C. Zubair, MD PhD, Mohamed A Kharfan-Dabaja, MDMBA

Blood (2019) 134 (Supplement_1): 5610.

DOI: https://doi.org/10.1182/blood-2019-122067

Published: 2019

2 3 4 5

NARROW

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma

Characteristics, Management and Outcomes of Patients with Intravascular Lymphoma: A Mayo Clinic Experience

Improved Clinical Outcome of Patients with Myelodysplastic Syndrome (MDS) Progressing after Hypomethylating Agent: In the Era of Novel Therapies

DDX41 Variant of Unknown Significance (VUS) Have Distinct Clinical and Diagnostic Features but Are Associated with Similar Prognosis and Co-Mutation Patterns As Pathogenic DDX41 : Analysis of the Mayo Clinic (MC) Myeloid Next-Generation Sequencing (NGS) Cohort

Trends in Utilization of Stored Cryopreserved Autologous Peripheral Hematopoietic Cells (APBHC) Intended for a Second (or beyond) Autologous Hematopoietic Cell Transplantation (AHCT) in Patients with Multiple Myeloma (MM): A Single Center Experience

Unique Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (trALL) Following Therapy for Multiple Myeloma (MM)

Primary Central Nervous System Involvement at Initial Diagnosis Remains an Independent Risk Factor for Relapse in Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation in CR1

Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy

A Calcineurin Inhibitor Free Graft Versus Host Disease (GVHD) Prophylaxis for Patients Undergoing Matched Related (MRD) and Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplant (Allo-HCT)

Significance of Degree of HLA Disparity When Using Haploidentical Donors with T-Replete PBSC and Post-Transplantation Cyclophosphamide (PTCy) in Acute Myeloid Leukemia (AML) in First Complete Hematologic Remission (CR1)

Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR

Impact of Cell of Origin (COO) on Long Term Outcomes Post Autologous Hematopoietic Cell Transplant in Patients with Relapsed/ Refractory Chemotherapy Sensitive De-Novo Diffuse Large B-Cell Lymphoma (DLBCL)

Superiority of Thiotepa-Containing Conditioning Regimens in Patients with Primary Diffuse Large B-Cell Lymphoma (DLBCL) of the Central Nervous System (CNS) Undergoing Autologous Hematopoietic Cell Transplantation (autoHCT)

Management of Patients with Aggressive B Cell Non-Hodgkin Lymphoma after Relapse from Axicabtagene Ciloleucel: Single Center Real-World Experience

Survival Outcomes in Blastic Plasmacytoid Dendritic Cell Neoplasm By First-Line Treatment and Stem Cell Transplant

Pre- Transplant Ferritin Predicts Overall Survival and Non-Relapse Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis

Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel)

Impact of Anti-CD19 CAR-T Axicabtagene Ciloleucel on Vaccine Titers of DTaP and MMR

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only